Unlike NSCLC, where biomarkers such as tumor mutation burden (TMB) and PD-L1 have shown predictive value for the response to ICIs, SCLC lacks reliable biomarkers for guiding effective therapies [57]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.